See more : ESR-Logos REIT (J91U.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Petra Acquisition, Inc. (PAICU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Petra Acquisition, Inc., a leading company in the Shell Companies industry within the Financial Services sector.
- Enorama Pharma AB (publ) (ERMA.ST) Income Statement Analysis – Financial Results
- Pricol Limited (PRICOLLTD.NS) Income Statement Analysis – Financial Results
- TST Group Holding Ltd. (4439.TW) Income Statement Analysis – Financial Results
- Anhui Estone Materials Technology Co.,Ltd (688733.SS) Income Statement Analysis – Financial Results
- Nordic Group Limited (MR7.SI) Income Statement Analysis – Financial Results
Petra Acquisition, Inc. (PAICU)
About Petra Acquisition, Inc.
Petra Acquisition, Inc. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2019 and is based in New York, New York.
| Metric | 2020 |
|---|---|
| Revenue | 0.00 |
| Cost of Revenue | 0.00 |
| Gross Profit | 0.00 |
| Gross Profit Ratio | 0.00% |
| Research & Development | 0.00 |
| General & Administrative | 145.49K |
| Selling & Marketing | 0.00 |
| SG&A | 145.49K |
| Other Expenses | 0.00 |
| Operating Expenses | 145.49K |
| Cost & Expenses | 145.49K |
| Interest Income | 10.92K |
| Interest Expense | 0.00 |
| Depreciation & Amortization | 9.08K |
| EBITDA | -136.41K |
| EBITDA Ratio | 0.00% |
| Operating Income | -145.49K |
| Operating Income Ratio | 0.00% |
| Total Other Income/Expenses | 9.08K |
| Income Before Tax | -136.41K |
| Income Before Tax Ratio | 0.00% |
| Income Tax Expense | 0.00 |
| Net Income | -136.41K |
| Net Income Ratio | 0.00% |
| EPS | -0.03 |
| EPS Diluted | -0.03 |
| Weighted Avg Shares Out | 4.37M |
| Weighted Avg Shares Out (Dil) | 4.37M |
Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal For NASDAQ Debut
Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded Through a Merger with Petra Acquisition, Inc.
PETRA ACQUISITION, INC. ANNOUNCES SECURITIES TO COMMENCE SEPARATE TRADING
U.S. IPO Week Ahead: Chinese EV's Billion-Dollar Deal Closes Out Summer In A 2-IPO Week
Source: https://incomestatements.info
Category: Stock Reports